Effect of a lipid-rich emollient containing ceramide 3 in experimentally induced skin barrier dysfunction.
In the present study we compared the effect of a ceramide 3-containing emollient (Locobase(R) Repair) with a control emollient (vaselinum album/cremor lanette ana) and untreated damaged skin using clinical, bioengineering and immunohistochemical methods in two different models of experimentally induced skin barrier dysfunction. In model A (n = 13) skin barrier dysfunction was inflicted at three investigation sites by tape stripping. In model B (n = 13) the volunteers were patch tested at three investigation sites with sodium dodecyl sulphate (0.2%) for 4 h a day for 4 consecutive days. The investigation sites were treated once a day with the above-mentioned agents. Irritant reaction was assessed daily by erythema scoring and measurements of transepidermal water loss (TEWL). After 5D, punch biopsies were taken from all sites. Immunohistochemical assessment was carried out with respect to epidermal proliferation, epidermal differentiation and Langerhans cells. Tape stripping resulted in an erythematous reaction and an increase of TEWL associated with up-regulation of cycling cells, involucrin and expression of cytokeratin 16. At day 4, ceramide 3-containing emollient significantly decreased (p < 0.03) the erythema score, TEWL and cycling cells in comparison with the untreated site. Repetitive exposure to SDS induced a variable degree of erythema, gradual increase of TEWL, an increase of cycling cells, and up-regulation of involucrin, E-FABP and SKALP. The treatment with the control emollient significantly prevented erythema, increase of TEWL and cycling cells at day 4 compared to the untreated site. In summary, the present study demonstrated that both tested emollients improve skin barrier in different conditions compared to the untreated skin. There is some indication that formulations containing skin-related lipids might be of benefit in barrier disruption following tape stripping. Different models and clinical trials are needed to establish the usefulness in specific conditions of emollients containing skin-related lipids.
Kucharekova
M
M
Department of Dermatology, University Hospital Nijmegen, the Netherlands. M.Kucharekova@derma.azn.nl
Schalkwijk
J
J
Van De Kerkhof
P C M
PC
Van De Valk
P G M
PG
D000279:Administration, Cutaneous; D000328:Adult; D002455:Cell Division / Q000187:drug effects; D017453:Dermatitis, Irritant / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D004643:Emollients / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006028:Glycosphingolipids / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007150:Immunohistochemistry; D007801:Langerhans Cells / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009930:Organic Chemicals; D010328:Patch Tests; D012016:Reference Values; D012867:Skin / Q000166:cytology / Q000187:drug effects* / Q000503:physiopathology; D012967:Sodium Dodecyl Sulfate; D014870:Water Loss, Insensible / Q000187:drug effects*
D004643:Emollients; D006028:Glycosphingolipids; D009930:Organic Chemicals; C085972:locobase; D012967:Sodium Dodecyl Sulfate; C018480:ceramide 3